Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHISH SUDHIR PATEL

Allopathic & Osteopathic Physicians Pediatrics Pediatric Gastroenterology

NPI
1053421636
CMS profile
47553
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$55,666.49

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $52,871.85 45
PFIZER INC. $2,220.00 1
Takeda Pharmaceuticals U.S.A., Inc. $235.43 3
E.R. Squibb & Sons, L.L.C. $121.84 1
Janssen Scientific Affairs, LLC $112.49 1
Celgene Corporation $84.50 1
QOL Medical, LLC $19.38 1
Travere Therapeutics, Inc. $1.00 1

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHISH SUDHIR PATEL

NPI 1053421636 · CMS profile ID 47553

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Gastroenterology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1053421636?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHISH SUDHIR PATEL, NPI 1053421636, CMS profile ID 47553. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1053421636?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ASHISH SUDHIR PATEL, NPI 1053421636, CMS profile ID 47553. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1053421636?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ASHISH SUDHIR PATEL, NPI 1053421636, CMS profile ID 47553, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1053421636?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $55,666.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Travere Therapeutics, Inc. $1.0002/23/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849791485 CMS
AbbVie Inc. $3,250.0002/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795529993 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.9001/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820133885 CMS
AbbVie Inc. $650.0001/07/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795529987 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,304.91 50
PY2020 $7,260.71 20
PY2021 $55,666.49 54
PY2022 $13,448.01 34
PY2023 $10,859.21 26
PY2024 $575.62 7
PY2025 $3,217.71 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $120,210.29 45
PY2024 Principal investigator $11,943.23 11
PY2023 Recipient $1,128.65 11
PY2023 Principal investigator $116,033.22 24
PY2022 Principal investigator $50,000.00 15
PY2021 Principal investigator $1,511.23 2
PY2020 Principal investigator $6,730.58 4
PY2019 Principal investigator $55,582.43 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,834.45 12/31/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418488
Principal investigator 1 ABBVIE INC. $33,098.29 12/16/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418480
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,800.00 12/12/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/05/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268818
Principal investigator 1 ABBVIE INC. $3,306.47 12/04/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418476
Principal investigator 1 ABBVIE INC. $2,048.24 11/04/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418454
Principal investigator 1 ABBVIE INC. $550.00 10/14/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418449
Principal investigator 1 ABBVIE INC. $18,869.86 10/09/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418442
Principal investigator 1 ABBVIE INC. $700.00 09/05/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418428
Principal investigator 1 ABBVIE INC. $6,687.00 09/05/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418431
Principal investigator 1 ABBVIE INC. $1,704.82 09/05/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418435
Principal investigator 1 ABBVIE INC. $500.00 09/05/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418438
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 09/03/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A STUDY OF VEDOLIZUMAB IN CHILDREN WITH ULCERATIVE COLITIS (UC) OR CROHN'S DISEASE (CD) No dispute reported 06/30/2026 1223268810
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,647.44 09/02/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268808
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 08/08/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A STUDY OF VEDOLIZUMAB IN CHILDREN WITH ULCERATIVE COLITIS (UC) OR CROHN'S DISEASE (CD) No dispute reported 06/30/2026 1223268806
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 08/06/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268802
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 08/06/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268804
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268792
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 08/01/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268794
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268796
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 08/01/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268800
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $250.00 07/09/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268786
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $34.58 07/09/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A STUDY OF VEDOLIZUMAB IN CHILDREN WITH ULCERATIVE COLITIS (UC) OR CROHN'S DISEASE (CD) No dispute reported 06/30/2026 1223268788
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 07/02/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268784
Principal investigator 1 ABBVIE INC. $350.00 06/10/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418420
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,801.78 05/23/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A STUDY OF VEDOLIZUMAB IN CHILDREN WITH ULCERATIVE COLITIS (UC) OR CROHN'S DISEASE (CD) No dispute reported 06/30/2026 1223268780
Principal investigator 1 ABBVIE INC. $300.00 04/08/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418397
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 04/04/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A STUDY OF VEDOLIZUMAB IN CHILDREN WITH ULCERATIVE COLITIS (UC) OR CROHN'S DISEASE (CD) No dispute reported 06/30/2026 1223268772
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 04/04/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A STUDY OF VEDOLIZUMAB IN CHILDREN WITH ULCERATIVE COLITIS (UC) OR CROHN'S DISEASE (CD) No dispute reported 06/30/2026 1223268774
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 04/02/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A STUDY OF VEDOLIZUMAB IN CHILDREN WITH ULCERATIVE COLITIS (UC) OR CROHN'S DISEASE (CD) No dispute reported 06/30/2026 1223268770
Principal investigator 1 ABBVIE INC. $450.00 03/19/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
M14-658 - Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418380
Principal investigator 1 ABBVIE INC. $9,497.00 03/19/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
M14-658 - Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418384
Principal investigator 1 ABBVIE INC. $800.00 03/13/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
M14-658 - Study to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202418372
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,450.00 02/26/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268758
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 02/26/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268760
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 02/26/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268762
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 02/26/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268764
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 02/26/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268766
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 02/26/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268768
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,750.00 02/14/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268756
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $830.36 02/03/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268744
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,000.00 02/03/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268746
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 02/03/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268748
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 02/03/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268750
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $450.00 02/03/2025 Covered Recipient Teaching Hospital
PHOENIX CHILDRENS HOSPITAL
A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB INTRAVENOUS AS MAINTENANCE THERAPY IN PEDIATRIC SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY No dispute reported 06/30/2026 1223268752